DIVI'S LABORATORIES LTD.

NSE : DIVISLABBSE : 532488ISIN CODE : INE361B01024Industry : Pharmaceuticals & DrugsHouse : Divis Labs
BSE3573.60-70.85 (-1.94 %)
PREV CLOSE ( ) 3644.45
OPEN PRICE ( ) 3636.55
BID PRICE (QTY) 3570.60 (20)
OFFER PRICE (QTY) 3573.60 (8)
VOLUME 5060
TODAY'S LOW / HIGH ( )3570.30 3647.20
52 WK LOW / HIGH ( )2730 4072.35
NSE3571.10-77 (-2.11 %)
PREV CLOSE( ) 3648.10
OPEN PRICE ( ) 3649.00
BID PRICE (QTY) 3571.10 (11)
OFFER PRICE (QTY) 3571.95 (1)
VOLUME 246609
TODAY'S LOW / HIGH( ) 3570.00 3655.00
52 WK LOW / HIGH ( )2730 4074.4
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 12-10 1990
Management Info
Ramesh BV Nimmagadda - Chairman Murali K Divi - Managing Director
Registered Office

Address 1-72/23( P)/ Divis/303,Divi Towers, Cyber Hills,Gachibowli,
Hyderabad,
Telangana-500032

Phone 040 66966300

Email mail@divislabs.com

Website www.divislabs.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS
12Feb Divi's Laboratories reports 17% rise i
Divi's Laboratories has reported results for third quarter ended Decembe..
12Feb Divi's Laboratories surges on reportin
Divi's Laboratories is currently trading at Rs. 3751.95, up by 100.95 po..
09Jan Divi's Laboratories informs about cert
Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Reg..
30Dec Divi's Laboratories informs about clos
Pursuant to the Company’s Code of Conduct for Prevention of Insider Trad..
16Nov Divi’s Laboratories informs about disc
Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obliga..
Financials
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit358018081.5
Gross Profit 4900 23541
Operating Profit 585026966.9
Net Sales 1808076253
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
AMI Organics (BSE)
 1116.90 (3.89%)
M.Cap (Rs. in Cr)4083.23
Glenmark Pharma (BSE)
 933.00 (3.63%)
M.Cap (Rs. in Cr)26474.89
Orchid Pharma (BSE)
 1248.55 (2.58%)
M.Cap (Rs. in Cr)6325.18
Concord Biotech (BSE)
 1500.05 (1.73%)
M.Cap (Rs. in Cr)15692.43
SMS Lifesciences (BSE)
 606.50 (3.95%)
M.Cap (Rs. in Cr)183.36
Shareholding Pattern
PROMOTERS 51.92%
MUTUAL FUNDS/UTI 13.72%
NON-INSTITUTION 11.34%
FI/BANKS/INSURANCE 7.43%
GOVERNMENT 0%
FII 0%
ATTENTION INVESTORSKYCIPO
Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do’s & Don’t’s) in Vernacular Language :
REGISTRATION NOS.

NSE CM-INZ000234235|NSE F& O - INZ000234235, NSE CD-INZ000234235, BSE CM–INZ000234235 |BSE F & O - INZ000234235|BSE CD- INZ000234235 MCX-SX CM-INZ000234235|MCX-SX F & O - INZ000234235|MCX-SX CD-INZ000234235 NSDL - IN-DP-NSDL-319-2009ROC REG - 21-097912,CDSL : IN-DP-242-2016|SEBI-PMS: INP000007100|LEI- 3358007DLCFNHY8J2F96

Filing compliant on SCORES – Easy & quick

  • Register on SCORES portal
  • Mandatory details for filing complaints on SCORES:
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • Benefits:
    • i.) Effective communication
    • ii.) Speedy redressal of the grievances
INVESTOR PROTECTION

Compliance officer : Apurva Mittal, Tel No: 022-40790035,022-40790024, Mobile No: 9152943075, E-mail ID: compliance@nnmsecurities.com, cdsl@nnmsecurities.com

Investor grievance : support@nnmsecurities.com

"NNM Securities has partnered with TradingView for its charting technology. An investment and trading platform empowering users with global market data and analytical tools like Stock Screener and Economic Calendar."

Copyright © 2021 NNM Securities.com

Advanced Charts Technology Partner: TradingView

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.